The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
Cilostazol 100 mg bid for 12 months
Aspirin 100 mg qd for 12 months
Peking University First Hospital
Beijing, Beijing Municipality, China
Shanghai Hua Shan Hospital
Shanghai, Shanghai Municipality, China
changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth
Time frame: one year
stroke recurrence, other vascular ischemic events, bleeding events
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.